STAT

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Vizitează neapărat site-ul podcastului și susține-i creatorul: soundcloud.com

Autor

STAT

Categorie

Business

Site-ul podcastului

soundcloud.com

Cel mai nou episod

13 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Episode 50: A big scoop on opioid marketing 22.02.2019

What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?

Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill 21.02.2019

Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering sche...

Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH 14.02.2019

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from? 07.02.2019

Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns 31.01.2019

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics 24.01.2019

Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics 17.01.2019

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?

Episode 43: A people's history of J.P. Morgan 10.01.2019

Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?

Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring 03.01.2019

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta 20.12.2018

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests 13.12.2018

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history 06.12.2018

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

Episode 38: Your guide to the #CRISPRbabies controversy 29.11.2018

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?

Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts 15.11.2018

Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug 08.11.2018

Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence 01.11.2018

Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?

Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma 25.10.2018

Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?

Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy 18.10.2018

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn 11.10.2018

Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?

Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round 04.10.2018

Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?

Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics 27.09.2018

Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?

Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem 20.09.2018

Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping 13.09.2018

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Episode 27: Live from Boston! 06.09.2018

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer 30.08.2018

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Ascultă podcastul The Readout Loud în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice